Overview

A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder

Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Double-blind, placebo-controlled, multiple ascending oral dose evaluation of the safety, tolerability, and pharmacokinetics of DSP 1053 and its metabolites in healthy subjects and in subjects with major depressive disorder
Phase:
Phase 1
Details
Lead Sponsor:
Sunovion